Merck & Co., Inc. vs Warner Music Group Corp — how do they compare? Merck & Co., Inc. trades at $144.69 (market cap $351.28B), while Warner Music Group Corp trades at $29.32 (market cap $15.12B). The key difference: Merck & Co., Inc. is far larger — about 23.2× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Warner Music Group Corp for 96 Days on average.
| MRK | WMG | |
|---|---|---|
Market Cap | $351.28B | $15.12B |
Volume | 7,969,665 | 2,966,414 |
Sector | Health | Media |
52-Week High | $156.43 | $34.72 |
52-Week Low | $82.49 | $23.65 |
Typical Hold Time | 98 Days | 96 Days |
Enterprise Value | $398.04B | $19.42B |
Dividend Yield | 2.39% | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Warner Music Group (WMG) trades at $28.16, up 1.99% today, with a bullish technical signal and strong analyst support. Recent earnings show revenue growth to $6.71B in 2025, though net income margin dipped to 5.44%. The company is actively engaging in AI partnerships and licensing renewals, positioning for future growth in the evolving media landscape.
The outlook for WMG is positive, driven by streaming growth and strategic AI initiatives, with a consensus price target of $39.50 implying significant upside. Risks include margin pressure and competitive dynamics in the music industry, but institutional buying and a 'Moderate Buy' consensus suggest confidence in its long-term value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →